Current Concepts
Treatment of Small Cell Lung Cancer
Abstract
The prognosis for patients with small cell lung cancer has improved over the past ten years from a median survival of 2.5 months to 8 to 10 months for patients with extensive metastatic disease and 12 to 16 months for patients with limited disease. This progress has been primarily through advances in chemotherapy. A small percentage of patients are having prolonged disease-free survival. Methods of staging are reviewed. The best current chemotherapeutic programs are discussed, as well as the present role of radiation therapy in the management of small cell lung cancer.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
